(canagliflozin)
This information is intended for US healthcare professionals to access current scientific information about Janssen products. It is prepared by Janssen Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 05/02/2023
A literature search of MEDLINE® (and/or other resources, including internal/external databases) pertaining to this topic was conducted through October 29, 2022. No published reports pertaining to this topic were identified.
1 | Center for Drug Evaluation and Research. Clinical Review. Canagliflozin. May 31, 2012. Page 24. |
2 | U.S. National Library of Medicine. National Institutes of Health. Health & Human Services. DailyMed. INVOKANA - canagliflozin tablet, film coated. Bethesda, MD. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3. Accessed February 16, 2017. |
3 | Janssen Research & Development, LLC. Investigator's Brochure. Canagliflozin. May 15, 2020. EDMS-ERI-13482463, 23.0. Page 33. |
4 | Desai PM Liew CV, Heng PWS. Review of Disintegrants and the Disintegration Phenomena. J Pharm Sci. 2016;105(9):2545-2555. . |
5 | Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry: Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation. March 2013. https://www.fda.gov/downloads/drugs/guidances/ucm269921.pdf. |
6 | APhA Strategic Directions Committee. Tablet splitting: evaluating appropriateness for patients. J Am Pharm Assoc. 2004;44(3):324-325. |
7 | American Society of Health-System Pharmacists (ASHP). 0525-Mandatory Tablet Splitting for Cost Containment. ASHP Policy Positions 1982-2016. https://www.ashp.org/pharmacy-practice/policy-positions-and-guidelines/browse-by-document-type/policy-positions. Accessed March 22, 2016. |